This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Albireo Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

62.9%

Wachstumsrate der Gewinne

61.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.4%
Wachstumsrate der Einnahmen	51.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	24 Feb 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Jan 02

Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Oct 25

Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome

Oct 11

These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Aug 23

Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M

Aug 15

Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation

Jul 22

Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

May 10

Albireo: A Speculative Play With Upside

May 03

Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?

Feb 02

Albireo: Successful And Accelerating Global Launch Drives Sales Revenue

Jan 31

Albireo: Reasons For A Successful Transformation Into A Commercial Company

Nov 24

Albireo Pharma: A Post Approval Assessment

Aug 09

Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress

Jun 21

Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year

Jun 11

Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat

Apr 26

Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts

Feb 27

Albireo launches late-stage trial of odevixibat in Alagille Syndrome

Dec 17

Albireo submits U.S. and European applications for odevixibat in liver disease

Dec 09

Albireo Pharma (ALBO) Investor Presentation - Slideshow

Nov 17

Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease

Nov 13

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ALBO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	248	-5	N/A	N/A	5
12/31/2024	128	-102	N/A	N/A	5
12/31/2023	61	-144	N/A	N/A	7
12/31/2022	35	-159	N/A	N/A	7
9/30/2022	57	-131	-116	-115	N/A
6/30/2022	51	-36	-114	-113	N/A
3/31/2022	45	-33	-109	-108	N/A
12/31/2021	41	-34	-108	-108	N/A
9/30/2021	11	-48	-122	-122	N/A
6/30/2021	9	-136	-121	-120	N/A
3/31/2021	9	-120	-112	-112	N/A
12/31/2020	8	-108	-101	-101	N/A
9/30/2020	12	-90	-85	-85	N/A
6/30/2020	11	-82	-73	-73	N/A
3/31/2020	11	-78	-64	-63	N/A
12/31/2019	10	-63	-53	-53	N/A
9/30/2019	4	-71	-51	-51	N/A
6/30/2019	3	-63	-47	-47	N/A
3/31/2019	2	-61	-41	-41	N/A
12/31/2018	13	-46	-27	-27	N/A
9/30/2018	12	-35	-25	-25	N/A
6/30/2018	12	-28	-20	-20	N/A
3/31/2018	11	-19	-18	-18	N/A
12/31/2017	0	-24	-28	-28	N/A
9/30/2017	3	-31	-26	-26	N/A
6/30/2017	3	-28	-25	-25	N/A
3/31/2017	11	-20	-15	-15	N/A
12/31/2016	11	-16	-9	-9	N/A
9/30/2016	13	-5	-1	-1	N/A
6/30/2016	13	-4	N/A	1	N/A
3/31/2016	5	-8	N/A	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALBO is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: ALBO is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: ALBO is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: ALBO's revenue (51.1% per year) is forecast to grow faster than the US market (6.9% per year).

Hohe Wachstumseinnahmen: ALBO's revenue (51.1% per year) is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if ALBO's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Albireo Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to US$49.86

Price target increased to US$56.86

Consensus revenue estimates fall by 25%

No longer forecast to breakeven

Consensus revenue estimates fall by 20%

Price target decreased to US$66.00

Recent updates

Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application

Chief Scientific Officer notifies of intention to sell stock

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Price target decreased to US$49.86

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Albireo Pharma, Inc. Submits Bylvay(R) Alagille Syndrome Regulatory Filings to FDA and EMA

Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson to its Board of Directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Albireo Pharma, Inc. Presents New Data at the American Association for the Study of Liver Diseases

Albireo Pharma, Inc. Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia

Albireo Pharma, Inc. to Present Late Breaking Bylvay (odevixibat) Data at AASLD 2022

Albireo Pharma, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Price target increased to US$56.86

Albireo Pharma, Inc. Reports Positive Topline Data from Phase 3 Trial of Bylvay® (Odevixibat) in Alagille Syndrome

Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome

Albireo to Showcase New Data at AASLD The Liver Meeting® 2022

Albireo Pharma: Assessing The Sagard Deal

Albireo gains on royalty agreement for pruritus therapy

Albireo Pharma, Inc. Announces Enabled Reimbursed Access to Bylvay for the Treatment of All Types of Progressive Familial Intrahepatic Cholestasis Patients in Italy

Albireo gets reimbursed access to liver disease drug Bylvay in Italy

These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Albireo Pharma, Inc. Announces New Committee Member Appointments

Consensus revenue estimates fall by 25%

No longer forecast to breakeven

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M

Albireo Pharma, Inc. Announces the Appointments of Habib Dable and Susan Alesina to its Board of Directors

Albireo Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation

Albireo Pharma, Inc. Announces Lancet Gastroenterology & Hepatology Published the Results of the Pivotal PEDFIC 1 Trial

Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from Russell Microcap Value Index

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

Albireo Pharma, Inc. Announces Presentation of New Data in Pediatric and Adult Liver Diseases

Consensus revenue estimates fall by 20%

Price target decreased to US$66.00

Albireo Pharma, Inc. Provides Sales Guidance for the Year 2022

Albireo Pharma, Inc. to Report Q1, 2022 Results on May 16, 2022

Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

Albireo Pharma, Inc. to Report Q1, 2022 Results on May 16, 2022

Albireo: A Speculative Play With Upside

Insufficient new directors

Albireo Pharma, Inc., Annual General Meeting, Jun 16, 2022

Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Albireo Pharma, Inc. Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease

Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?

Albireo: Successful And Accelerating Global Launch Drives Sales Revenue

CEO, President & Director notifies of intention to sell stock

Consensus forecasts updated

Forecast to breakeven in 2024

Albireo Announces Positive Topline Data from Phase 1 Study of A3907

Albireo Pharma, Inc. Presenting New Bylvay™ (Odevixibat) Data at NASPGHAN 2021

Albireo: Reasons For A Successful Transformation Into A Commercial Company

Third quarter 2021 earnings released: EPS US$2.96 (vs US$1.96 loss in 3Q 2020)

Chief Legal Officer notifies of intention to sell stock

CEO, President & Director exercised options and sold US$81k worth of stock

Albireo Pharma, Inc. Receives UK MHRA Approval of Bylvay® (odevixibat)

Consensus revenue estimates increase to US$39.1m

Albireo Pharma: A Post Approval Assessment

Second quarter 2021 earnings released: US$1.90 loss per share (vs US$1.38 loss in 2Q 2020)

Albireo Pharma, Inc. Announces European Commission Authorization of Bylvay (Odevixibat), the First Drug Approved for the Treatment of All Subtypes of Progressive Familial Intrahepatic Cholestasis

Chief Legal Officer exercised options and sold US$196k worth of stock

Albireo Pharma, Inc. Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming Easl International Liver Congress

Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress